These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8340606)

  • 1. Serum and salivary caffeine clearance in cirrhosis. Any role in selection for surgery and timing for transplantation?
    Farinati F; Dalri L; Rossaro L; Plebani M; Nemetz L; Boccagni P; Bassi N; Naccarato R
    J Hepatol; 1993 Apr; 18(1):135-6. PubMed ID: 8340606
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night.
    Wahlländer A; Mohr S; Paumgartner G
    J Hepatol; 1990 Mar; 10(2):129-37. PubMed ID: 2185297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability of total overnight salivary caffeine assessment (TOSCA) for liver function evaluation in compensated cirrhotic patients.
    Tarantino G; Conca P; Capone D; Gentile A; Polichetti G; Basile V
    Eur J Clin Pharmacol; 2006 Aug; 62(8):605-12. PubMed ID: 16841221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeine clearance in cirrhosis. The value of simplified determinations of liver metabolic capacity.
    Lewis FW; Rector WG
    J Hepatol; 1992 Mar; 14(2-3):157-62. PubMed ID: 1500679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.
    Scott NR; Stambuk D; Chakraborty J; Marks V; Morgan MY
    Br J Clin Pharmacol; 1989 Feb; 27(2):205-13. PubMed ID: 2713214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeine clearance and biotransformation in patients with chronic liver disease.
    Scott NR; Stambuk D; Chakraborty J; Marks V; Morgan MY
    Clin Sci (Lond); 1988 Apr; 74(4):377-84. PubMed ID: 3356110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeine clearance study in hepatocellular carcinoma.
    Tangkijvanich P; Wittayalertpanya S; Kusonsolboon T; Thong-Ngam D; Mahachai V
    J Med Assoc Thai; 1999 Mar; 82(3):297-303. PubMed ID: 10410486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis.
    Shyu JK; Wang YJ; Lee SD; Lu RH; Lo KJ
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 May; 57(5):329-34. PubMed ID: 8768380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis].
    Perlík F; Pucelíková T; Slanar O
    Cas Lek Cesk; 2001 Feb; 140(2):51-3. PubMed ID: 11262908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum metabolite/caffeine ratios as a test for liver function.
    Jodynis-Liebert J; Flieger J; Matuszewska A; Juszczyk J
    J Clin Pharmacol; 2004 Apr; 44(4):338-47. PubMed ID: 15051740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of liver disease on urine caffeine metabolite ratios.
    Denaro CP; Wilson M; Jacob P; Benowitz NL
    Clin Pharmacol Ther; 1996 Jun; 59(6):624-35. PubMed ID: 8681487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function.
    Cheng WS; Murphy TL; Smith MT; Cooksley WG; Halliday JW; Powell LW
    Clin Pharmacol Ther; 1990 Apr; 47(4):516-24. PubMed ID: 2328560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diurnal effect on caffeine clearance.
    Hashiguchi M; Fujimura A; Ohashi K; Ebihara A
    J Clin Pharmacol; 1992 Feb; 32(2):184-7. PubMed ID: 1613129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis.
    Bianchetti MG; Kraemer R; Passweg J; Jost J; Preisig R
    J Pediatr Gastroenterol Nutr; 1988; 7(5):688-93. PubMed ID: 3183872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary caffeine clearance predicts survival in patients with liver cirrhosis.
    Jover R; Carnicer F; Sánchez-Payá J; Climent E; Sirvent M; Marco JL
    Am J Gastroenterol; 1997 Oct; 92(10):1905-8. PubMed ID: 9382063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of caffeine and dimethylxanthines in plasma and saliva].
    Nakazawa K; Tanaka H
    Yakugaku Zasshi; 1988 Jul; 108(7):653-8. PubMed ID: 3241301
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
    Perera V; Gross AS; Xu H; McLachlan AJ
    J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of caffeine elimination and Child's classification in liver cirrhosis.
    Holstege A; Staiger M; Haag K; Gerok W
    Klin Wochenschr; 1989 Jan; 67(1):6-15. PubMed ID: 2921843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function.
    McDonagh JE; Nathan VV; Bonavia IC; Moyle GR; Tanner AR
    Gut; 1991 Jun; 32(6):681-4. PubMed ID: 2060878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.